

Supplemental Table II. Efficacy of CPX-351 against PPTP Xenograft Models

Study Information			Animal Counts/Status				EFS Evaluation			Response Evaluation								Overall Group Response				
Tumor Type	Cell Line	Line Description	Group	N1 ³	Nd ⁴	No ⁵	Na ⁶	No. ev ⁷	KM med. ⁸	Log-Rank P-value ⁹	EFS T/C ¹⁰	Median RTV/CD45% at end of study ¹¹	PD	PD1	PD2	SD	PR	CR	MCR	Median Score		
ALL B-precursor	G1	ALL-2	A ¹	9	0	0	9	9	10.8			>25	9	0	0	0	0	0	0	0	0.0	PD
			B ²	8	0	0	8	5	41.9	<0.001	3.9	>25	0	0	0	0	1	7	0	0	8.0	CR
ALL B-precursor	G3	ALL-4	A	8	0	4	4	4	5.6			>25	4	0	0	0	0	0	0	0	0.0	PD
			B	9	1	3	5	3	33.8	0.024	6.0	>25	0	0	0	0	2	3	0	0	8.0	CR
ALL B-precursor	G4	ALL-7	A	8	0	0	8	8	2.4			>25	8	0	0	0	0	0	0	0	0.0	PD
			B	7	0	1	6	6	34.3	<0.001	14.1	>25	0	0	0	0	1	5	0	0	8.0	CR
ALL T-cell	G5	ALL-8	A	8	0	0	8	8	10.8			>25	8	0	0	0	0	0	0	0	0.0	PD
			B	7	0	0	7	7	32.8	<0.001	3.0	>25	0	0	0	0	4	3	0	0	6.0	PR
ALL B-precursor	G8	ALL-19	A	8	0	0	8	8	8.4			>25	8	0	0	0	0	0	0	0	0.0	PD
			B	8	0	1	7	7	35.4	<0.001	4.2	>25	0	0	0	0	1	6	0	0	8.0	CR

¹ A: Control; ² B: Treated; ³ N1 – number of mice in group; ⁴ Nd – number of mice that experienced toxic deaths; ⁵ No – number of additional mice excluded; ⁶ Na – number of mice analyzed; ⁷ Number of events. An event was defined as reaching $\geq 25\%$ hCD45 cells in the peripheral blood; ⁸ Kaplan-Meier estimate of median days to event. Time to event was estimated using interpolation; ⁹ P-value comparing EFS of control and treated groups; ¹⁰ relative T/C at event; ¹¹ median hCD45% in the peripheral blood at the end of the study.